MedTrace Logo

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT07689188 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-07-09

No results posted yet for this study

Summary

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

DRUG

Roflumilast 0.3% topical foam

Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.

Sponsors & Collaborators

  • Harrison Dermatology

    lead UNKNOWN

Principal Investigators

  • HARRISON NGUYEN, MD, MBA, MPH, FAAD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-10
Primary Completion
2028-03-10
Completion
2028-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07689188 on ClinicalTrials.gov